Evidence map›Paper›PMID 27272954›Full record

ArticleMolecular diversity2016

Synthesis of isoindolin-1-one derivatives via multicomponent reactions of methyl 2-formylbenzoate and intramolecular amidation.

Jie Lei, Zhi-Gang Xu, Shi-Qiang Li, Jia Xu, Jin Zhu, Zhong-Zhu Chen

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jie LeiKey Laboratory for Asymmetric Synthesis and Chiral Technology of Sichuan Province, Chengdu Institute of Organic Chemistry, Chinese Academy of Sciences, Chengdu, 610041, China.
Zhi-Gang XuChongqing Engineering Laboratory of Targeted and Innovative Therapeutics, Chongqing Key Laboratory of Kinase Modulators as Innovative Medicine, IATTI, Chongqing University of Arts and Sciences, No. 319 Honghe Ave., Yongchuan, Chongqing, 402160, China. xuzhigangyours@yahoo.com.
Shi-Qiang LiChongqing Engineering Laboratory of Targeted and Innovative Therapeutics, Chongqing Key Laboratory of Kinase Modulators as Innovative Medicine, IATTI, Chongqing University of Arts and Sciences, No. 319 Honghe Ave., Yongchuan, Chongqing, 402160, China.
Jia XuChongqing Engineering Laboratory of Targeted and Innovative Therapeutics, Chongqing Key Laboratory of Kinase Modulators as Innovative Medicine, IATTI, Chongqing University of Arts and Sciences, No. 319 Honghe Ave., Yongchuan, Chongqing, 402160, China.
Jin ZhuUniversity of Chinese Academy of Sciences, Beijing, 100049, China.
Zhong-Zhu ChenChongqing Engineering Laboratory of Targeted and Innovative Therapeutics, Chongqing Key Laboratory of Kinase Modulators as Innovative Medicine, IATTI, Chongqing University of Arts and Sciences, No. 319 Honghe Ave., Yongchuan, Chongqing, 402160, China. 18883138277@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Four series of heterocyclic compounds were obtained using Ugi-type multicomponent reactions (MCRs) with methyl 2-formylbenzoate as one of the starting materials. A facile and efficient one-pot procedure was suitable for all the MCRs under acidic conditions. This process provided access to four series of complex and potentially biologically active scaffolds.

Indexed as

Combinatorial Chemistry TechniquesCyclizationHeterocyclic CompoundsIsoindolesMolecular StructureHeterocyclic CompoundsIsoindolesCyclizationHeterocyclesIntramolecular amidationMCRsOne-pot procedureUDC strategyUgi-type multicomponent reactions

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.